Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Cefimax

Approved

STANDARD

Cefimax

J.M. Tolmann Laboratories, Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: baee88071cd13e5f
Company: J.M. Tolmann Laboratories, Inc.
Type: Standard

Approval Details

Approval Id: baee88071cd13e5f
Drug Approval Philippines Name: Cefimax
Product Name: Cefimax
Registration Number: DRP-5052-10
Brand Name: Cefimax
Generic Name: Cefixime (as Trihydrate)
Dosage Form: Granules for Suspension
Dosage Strength: 100 mg/5 mL
Manufacturer: J.M. Tolmann Laboratories, Inc.
Distributor: Basic Pharmaceutical Corporation
Issuance Date: 29 November 2023
Expiry Date: 18 August 2027
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

baee88071cd13e5f

Type

Standard

Back to Philippines FDA Approvals

Cefimax - Philippines FDA Drug Approval Details